Dapagliflozin D5 (BMS-512148 D5) is the penta-deuterated form of Dapagliflozin. Dapagliflozin is a competitive SGLT2 inhibitor approved in 2012 by FDA for the treatment of type 2 diabetes.

纯度：≥98%

CAS：1204219-80-6